In vivo delivery of recombinant human growth hormone from genetically engineered human fibroblasts implanted within Baxter immunoisolation devices

S. F. Josephs, T. Loudovaris, A. Dixit, S. K. Young, R. C. Johnson

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Continuous delivery of therapeutic peptide to the systemic circulation would be the optimal treatment for a variety of diseases. The Baxter TheraCyte® system is a membrane encapsulation system developed for implantation of tissues, cells such as endocrine cells or cell lines genetically engineered for therapeutic peptide delivery in vivo. To demonstrate the utility of this system, cell lines were developed which expressed human growth hormone (hGH) at levels exceeding 1 microgram per million cells per day. These were loaded into devices which were then implanted into juvenile nude rats. Significant levels of hGH of up to 2.5 ng/ml were detected in plasma throughout the six month duration of the study. In contrast, animals implanted with free cells showed peak plasma levels of 0.5 to 1.2 ng four days after implantation with no detectable hGH beyond 10 days. Histological examination of explanted devices showed they were vascularized and contained cells that were viable and morphologically healthy. After removal of the implants, no hGH could be detected which confirmed that the source of hGH was from cells contained within the device. The long term expression of human growth hormone as a model peptide has implications for the peptide therapies for a variety of human diseases using membrane encapsulated cells.

Original languageEnglish (US)
Pages (from-to)211-214
Number of pages4
JournalJournal of Molecular Medicine
Volume77
Issue number1
DOIs
StatePublished - 1999
Externally publishedYes

Keywords

  • Baxter TheraCyte® system
  • Biomaterials
  • Gene therapy
  • Human growth hormone
  • Peptide delivery

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery
  • Genetics(clinical)

Fingerprint

Dive into the research topics of 'In vivo delivery of recombinant human growth hormone from genetically engineered human fibroblasts implanted within Baxter immunoisolation devices'. Together they form a unique fingerprint.

Cite this